These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 30076486)

  • 21. CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity.
    Franco-Tormo MJ; Salas-Crisostomo M; Rocha NB; Budde H; Machado S; Murillo-Rodríguez E
    J Mol Neurosci; 2018 May; 65(1):10-16. PubMed ID: 29732484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.
    Peddle CF; MacLaren RE
    Yale J Biol Med; 2017 Dec; 90(4):533-541. PubMed ID: 29259519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Cas9: from Genome Editing to Cancer Research.
    Chen S; Sun H; Miao K; Deng CX
    Int J Biol Sci; 2016; 12(12):1427-1436. PubMed ID: 27994508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases.
    Rahman S; Datta M; Kim J; Jan AT
    Semin Cell Dev Biol; 2019 Dec; 96():22-31. PubMed ID: 31102655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research.
    Aquino-Jarquin G
    Cancer Res; 2017 Dec; 77(24):6812-6817. PubMed ID: 29208606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral Delivery Systems for CRISPR.
    Xu CL; Ruan MZC; Mahajan VB; Tsang SH
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
    Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
    Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications.
    Ma X; Zhu Q; Chen Y; Liu YG
    Mol Plant; 2016 Jul; 9(7):961-74. PubMed ID: 27108381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.
    Pini V; Mariot V; Dumonceaux J; Counsell J; O'Neill HC; Farmer S; Conti F; Muntoni F
    Sci Rep; 2022 Mar; 12(1):3756. PubMed ID: 35260651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic applications of CRISPR/Cas9 system in gene therapy.
    Mollanoori H; Teimourian S
    Biotechnol Lett; 2018 Jun; 40(6):907-914. PubMed ID: 29704220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and therapy with CRISPR advanced CRISPR based tools for point of care diagnostics and early therapies.
    Uppada V; Gokara M; Rasineni GK
    Gene; 2018 May; 656():22-29. PubMed ID: 29496558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalised genome editing - The future for corneal dystrophies.
    Moore CBT; Christie KA; Marshall J; Nesbit MA
    Prog Retin Eye Res; 2018 Jul; 65():147-165. PubMed ID: 29378321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manipulating the Biosynthesis of Bioactive Compound Alkaloids for Next-Generation Metabolic Engineering in Opium Poppy Using CRISPR-Cas 9 Genome Editing Technology.
    Alagoz Y; Gurkok T; Zhang B; Unver T
    Sci Rep; 2016 Aug; 6():30910. PubMed ID: 27483984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics.
    Bhardwaj S; Kesari KK; Rachamalla M; Mani S; Ashraf GM; Jha SK; Kumar P; Ambasta RK; Dureja H; Devkota HP; Gupta G; Chellappan DK; Singh SK; Dua K; Ruokolainen J; Kamal MA; Ojha S; Jha NK
    J Adv Res; 2022 Sep; 40():207-221. PubMed ID: 36100328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR-Cas9 as a Tool in Cancer Therapy.
    Zatloukalová P; Krejčíř R; Valík D; Vojtěšek B
    Klin Onkol; 2019; 32(Supplementum 3):13-18. PubMed ID: 31627701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.